{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:57:21Z","timestamp":1760889441787},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3501-4","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T08:58:04Z","timestamp":1501232284000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer\/T-cell lymphoma patient with multi-line resistance: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Jianping","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"issue":"25","key":"3501_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(25):4124\u201330.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"3501_CR2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/PAS.0b013e31821ec4b5","volume":"35","author":"G Gualco","year":"2011","unstructured":"Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK\/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol. 2011;35(8):1195\u2013203.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"3501_CR3","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1111\/j.1365-2230.2009.03428.x","volume":"34","author":"HY Chia","year":"2009","unstructured":"Chia HY, Tey HL, Tan KB, Chong WS. Nasal-type extranodal natural killer\/T-cell lymphoma presenting with extensive leg ulcers. Clin Exp Dermatol. 2009;34(8):e693\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"3501_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(1):181\u20139.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"3501_CR5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00277-015-2336-9","volume":"94","author":"XW Bi","year":"2015","unstructured":"Bi XW, Jiang WQ, Zhang WW, Huang JJ, Xia Y, Wang Y, Sun P, Li ZM. Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Ann Hematol. 2015;94(7):1175\u201384.","journal-title":"Ann Hematol"},{"issue":"5","key":"3501_CR6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12185-012-1174-y","volume":"96","author":"L Wang","year":"2012","unstructured":"Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE\/IIE extranodal natural killer\/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96(5):617\u201323.","journal-title":"Int J Hematol"},{"issue":"3","key":"3501_CR7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","volume":"94","author":"M Kim","year":"2015","unstructured":"Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III\/IV NK\/T cell-lymphoma, nasal type (NTCL). Ann Hematol. 2015;94(3):437\u201344.","journal-title":"Ann Hematol"},{"issue":"4","key":"3501_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"4","key":"3501_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"3501_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","volume":"12","author":"WS Kim","year":"2001","unstructured":"Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma? Annals of oncology : official journal of the European Society for Medical Oncology. 2001;12(3):349\u201352.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"32","key":"3501_CR11","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","volume":"30","author":"M Yamaguchi","year":"2012","unstructured":"Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, et al. Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(32):4044\u20136.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"15","key":"3501_CR12","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973\u201380.","journal-title":"Blood"},{"issue":"6","key":"3501_CR13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834\u20139.","journal-title":"Blood"},{"issue":"20","key":"3501_CR14","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","volume":"7","author":"JH Wang","year":"2016","unstructured":"Wang JH, Wang L, Liu CC, Xia ZJ, Huang HQ, Lin TY, Jiang WQ, Lu Y. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma. Oncotarget. 2016;7(20):29092\u2013101.","journal-title":"Oncotarget"},{"issue":"8","key":"3501_CR15","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(8):1766\u201371.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"11","key":"3501_CR16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-014-2136-7","volume":"93","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed\/refractory extranodal NK\/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014;93(11):1889\u201394.","journal-title":"Ann Hematol"},{"issue":"1","key":"3501_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/imt.15.103","volume":"8","author":"T Kumai","year":"2016","unstructured":"Kumai T, Kobayashi H, Harabuchi Y. Novel targets for natural killer\/T-cell lymphoma immunotherapy. Immunotherapy. 2016;8(1):45\u201355.","journal-title":"Immunotherapy"},{"issue":"17","key":"3501_CR18","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TS, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437\u201342.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T08:58:07Z","timestamp":1501232287000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3501"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3501-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"article-number":"507"}}